Direct Oral Anticoagulants in Obesity: An Updated Literature Review

202038 citationsReview

Authors

Denise Kelley · Seton Medical Center Austin

Abstract

Evidence indicates that each DOAC may have differences in outcomes when used in patients with a high BW/BMI. Currently, low-quality data are available that support avoiding dabigatran and considering apixaban or rivaroxaban; lack of sufficient data preclude a recommendation for edoxaban use in this patient population.

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Blood Pressure and Hypertension Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Pharmacotherapy

Volume 54, Issue 11, pp. 1144-1158

DOI: 10.1177/1060028020923584

Field-Weighted Citation Impact: 3.72